Newsletter · 2026-07-03 · Ashutosh Agarwal

Pharma M&A Hits $123B as the Patent Cliff Bites - The Biotech Patent Cliff & M&A - Week of June 29 to July 3, 2026

Big Pharma's M&A supercycle hit $123B across 32 billion-dollar deals as $300B of revenue rolls off patent, with AbbVie's $10.9B Apogee takeout setting the template and a US-China trials probe landing on Merck and AbbVie. Our synthesis of the biotech M&A podcast tape for the week of June 29 to July 3, 2026.

The Biotech Patent Cliff & M&A

Week of June 29 to July 3, 2026: Pharma M&A Hits $123B as the Patent Cliff Bites

TL;DR

• The buying wave is now a supercycle. 32 deals of $1B+ worth ~$123B so far in 2026, on pace for the biggest M&A year since 2019, with ~$300B of annual revenue rolling off patent and ~70 blockbusters losing exclusivity in the next couple of years.
• AbbVie set the template again with its $10.9B Apogee takeout (49% premium, an immunology bolt-on), while a fresh US-China trials probe into Merck and AbbVie and Merck quietly killing a Phase 2 Alzheimer's program are the week's reminders that the buyers have problems of their own.
• Silence is the tell. Almost the entire SMID target list, Summit, Madrigal, Viking, Cytokinetics, Insmed, Krystal, Vaxcyte, Roivant, Revolution Medicines, went dark on the tape this week. No new rumors. The cash is real; the named targets aren't moving yet.

What's new

1. The M&A tape is running hot, and the numbers are getting silly. On Motley Fool Hidden Gems' "Big Pharma Has a Case of Merger Mania" (June 23), contributor Matt Frankel put hard numbers on the mood: "we've already seen 32 separate deals worth a billion dollars or more for a total deal value of $123 billion... the strongest year for M&A in the space since 2019." His co-host Lou Whiteman framed the why in one line: "an estimated $300 billion in annual revenue coming off patent in the next few years," and Frankel added the part PMs should tattoo on their monitors: "Almost 70 drugs that each generate over a billion dollars of revenue have their patents expiring within the next couple of years... it could drop 80 to 90% overnight." Note the structural shift: this is a bolt-on wave, not a mega-merger wave. Merck alone "made three major acquisitions in the last 10 months," all defense against the Keytruda cliff. This is the whole thesis of this letter, quantified.

2. AbbVie bought the wave's marquee asset, and told you why. Multiple shows dissected the $10.9B Apogee deal, but the cleanest operator quote came on Citeline's Scrip Five Must-Know Things (June 29): AbbVie CEO Robert Michael said the deal brings "multiple differentiated pipeline candidates that should provide mega-blockbuster revenue," aimed at the 2030s. On Brew Markets (June 22), John Croteau nailed the terms: "$135 a share in cash, a 49% premium," and the stakes: Skyrizi + Rinvoq immunology "brought in $7.3 billion... nearly half of the company's total revenue," even as Humira has cratered "nearly 40 percent to $688 million" post-2023 LOE. On BioCentury This Week Ep. 373 (June 23), news editor Paul Bananos flagged the read-through: lead asset Zumilokibat doses "every three months" versus Lilly's Ebglis and Sanofi/Regeneron's Dupixent at "every two to four weeks," and reminded listeners GSK just paid "close to $11 billion for New Valence," its third deal under new CEO Luke Miels. Two ~$11B immunology bolt-ons in a month tells you where the buyers think the next Humira-sized hole is.

3. An operator just described the patent cliff as an M&A engine, from the inside. On Venrock's Running Through Walls (June 23), MetSera CEO Whit Bernard walked through how Pfizer won his ultra-long-acting GLP-1 (Meta-097, an "18, 19 day observed half-life" monthly shot), and then, "about a month later," got a topping bid from Novo's CEO by letter, "which... really just doesn't happen in biopharma." His tell on buyer psychology: the asset was valuable because it "address[es] a revenue gap associated with a patent cliff in 2029, 2030... the problem that our colleagues at Pfizer needed to solve strategically." That's the demand curve for late-stage assets, narrated by the person who sold into it.

4. Two fresh overhangs on the biggest buyers. A bipartisan House China Select Committee opened a national-security probe into whether Merck and AbbVie ran clinical trials in China (Xinjiang, military hospitals) that aided the PLA, asking both to respond by July 17 (Reuters, June 30). Separately, Merck quietly terminated its Phase 2 Alzheimer's study of MK-1167 for a "business reason" (ClinicalTrials.gov, July 1). This dovetails with a policy angle from the Scrip (June 29) BIO panel: J&J's Leslie Stoltz and Sanofi's Brian Bronk (both operators) warned that proposed US screening of China biopharma deals is already killing transactions: Bronk said one deal died "because the potential partner was based in China." The cheapest late-stage pipelines sit in China; Washington is quietly raising the price of shopping there.

5. The GLP-1 kings keep diverging. On Wall Street Wildlife E138 (June 28), a Novo shareholder laid out the split with unusual candor: Lilly holds "60-40" of the GLP-1 market; CagriSema "lost" its February head-to-head and "Novo's stock dropped about 15% in a day... $100 billion in market cap" gone. Novo now trades "around 10 times earnings" versus Lilly at "around 40 times," is running "$2.3 billion worth of buybacks," has cut "11% of the global workforce," and is "down like 45% over the last year." Meanwhile BioCentury Ep. 374 (June 29) laid out AstraZeneca's five-program obesity push, including an activin asset (AZD-1043, from the SixPeaks takeout) targeting "10% weight loss as monotherapy." The obesity duopoly is drawing a determined third entrant with a checkbook.

The debate

The supercycle bull: The math is unarguable: ~$300B of revenue and ~70 blockbusters go off-patent, and Big Pharma has to buy growth or shrink. A friendlier FDA (post-Prasad rare-disease reversals) has re-rated clinical-stage assets that were "marked down," and Lilly's tirzepatide cash gusher, Evaluate projects it "over 70 billion dollars by 2032, the biggest drug ever," per Scrip (June 29), funds a bottomless bid. Premiums are climbing (STAT's Allison DeAngelis, citing PitchBook, on Readout Loud 407, notes the reopened IPO market is pushing sellers to hold out). Own quality SMID assets and collect the takeout premium.

The cliff-erosion bear: Bolt-ons don't fix an 80-90% overnight revenue cliff; they paper over it and dilute returns. Over the past decade "only three" of the dozen largest pharmas beat the S&P 500 (Motley Fool, June 23): this is a serial value-destroyer of an industry buying at 49% premiums into policy chaos (MFN pricing, a China-deal chill, and now a national-security probe into the two most cliff-exposed buyers). The Novo story is the warning label: cheap can get cheaper when the science slips.

My take: Both are right, which is exactly why this is a stock-picker's cliff, not a sector trade, as Whiteman put it, "I would hate to buy an ETF for this industry." The wave is real and self-reinforcing (sellers now have IPO optionality, so premiums rise), but the buyers' own overhangs mean the safer expression is owning the targets, not the acquirers. And the loudest signal this week was the quiet: the named SMID target list didn't move. When the tape is this hot and Summit/Viking/Cytokinetics still aren't generating rumors, the market is telling you the next leg is about price discovery on premiums, not a scramble for scarce assets. Stay long optionality, short the idea that any single acquirer is "safe."

Stocks in play

Read-throughs

• Likely takeout targets: The tape is loud on deals done and silent on deals next. With premiums rising on IPO optionality, expect buyers to move faster on de-risked, late-stage, immunology/obesity/oncology assets, the AbbVie/GSK immunology double-tap is the pattern. Watch obesity adjacencies (AZ's build-out validates the category's depth) and RAS/precision-onc names.
• Biosimilar makers: Humira's "−40% to $688M" is the live case study in how fast a biologic franchise unwinds once biosimilars land, and J&J's competing pill against Skyrizi shows the next erosion vector is oral convenience, not just price. Stelara biosimilar dynamics were quiet this week; that's a gap to fill, not a signal of calm.
• SMID / XBI sentiment: A reopened IPO window plus record M&A dollars is a constructive backdrop for small-cap biotech risk appetite, but the lack of named-target rumors argues the beta trade is ahead of the single-name trade.
• Bankers / CROs: 32 billion-dollar deals and counting is a banner fee environment; the China-deal chill (per the Sanofi/J&J operators) redirects sourcing toward US/EU assets, which is margin-positive for domestic advisers and pressures China-exposed CRO pipelines.

What changed vs last week

This is the inaugural issue, no prior letter to diff against. Consider this the baseline: the M&A supercycle is confirmed and quantified ($123B / 32 deals), AbbVie is the template setter, Lilly is the balance-sheet whale, Novo is the cautionary tale, and the named SMID target list is, notably, quiet. From here we track deltas: rumors that become deals, deals that close or break, and which of the silent names finally starts generating chatter. Next Friday we'll have something to compare to.